Efficacy of Tafasitamab

The combination of tafasitamab (Tafasitamab) and lenalidomide has a clear safety profile and is the preferred option in NCCN guidelines. It is suitable for patients with relapsed or refractory diffuse large B-cell lymphoma who are not suitable for transplantation and who have relapsed more than 12 months after first-line treatment. In most patients, lenalidomide-induced toxicity can be controlled with dose adjustment and supportive therapy, including growth factor support.

The combination of tafasitamumab and lenalidomide was studied ina study involving 81 adults with diffuse large B-cell lymphoma who had not responded to other treatments and were ineligible for autologous stem cell transplantation. In this study, patients received tafracetamumab and lenalidomide for up to 12 cycles and then tafracetamumab alone until disease progression or side effects became unmanageable. Of the patients in the study, 46 (57%) had a complete response (no evidence of cancer) or a partial response. According to the prescribing information, no clinically significant differences in tafasistatumab pharmacokinetics were observed based on age (16-90 years), mild to moderate renal impairment, or mild hepatic impairment; no dose adjustment of tafasistatumab was required in these populations.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.